Illumina ( (ILMN) ) has released its Q4 earnings. Here is a breakdown of the information Illumina presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Illumina, Inc. is a leading company in the genomics industry, specializing in DNA sequencing and array-based technologies for research, clinical, and applied markets. In its fourth-quarter and fiscal year 2024 earnings report, Illumina announced a slight increase in quarterly revenue and a decrease in annual revenue compared to the previous year, reflecting the company’s ongoing adjustments post-GRAIL spin-off. The company reported fourth-quarter revenue of $1.1 billion and fiscal year revenue of $4.3 billion, with a GAAP operating margin of 15.8% and 34.0% respectively. Notably, Illumina’s free cash flow for the fiscal year was $1.1 billion, indicating a strong cash position. Additionally, Illumina has made strategic collaborations, including partnerships with NVIDIA and Regeneron, to enhance its multiomic data analysis and genomic profiling capabilities. Looking forward, Illumina expects a low single-digit revenue growth for fiscal year 2025, maintaining a focus on operational excellence and customer-centric innovation.
